By hijacking NRG1 addiction of cancer cells to promote its inhibitory effects on NRG1-mediated tumor growth and resistance, the allosteric non NRG1-competing 9F7-F11 displays a unique potential for targeted treatment of NRG1-positive cancers [32]. This evidence concerns the gene NRG1 and cancer.